---
title: "Truist Financial Sticks to Its Hold Rating for Inspire Medical Systems (INSP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285199994.md"
description: "Truist Financial analyst Richard Newitter has maintained a Hold rating on Inspire Medical Systems (INSP) with a price target of $50.00. Newitter, a 4-star analyst, has an average return of 6.6% and a 45.53% success rate. KeyBanc also issued a Hold rating for the company, while Stifel Nicolaus maintained a Buy rating on the same day."
datetime: "2026-05-05T11:46:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285199994.md)
  - [en](https://longbridge.com/en/news/285199994.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285199994.md)
---

# Truist Financial Sticks to Its Hold Rating for Inspire Medical Systems (INSP)

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Inspire Medical Systems, with a price target of $50.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Newitter is a 4-star analyst with an average return of 6.6% and a 45.53% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific, Insulet, and Medtronic.

In addition to Truist Financial, Inspire Medical Systems also received a Hold from KeyBanc’s Brett Fishbin in a report issued today. However, on the same day, Stifel Nicolaus maintained a Buy rating on Inspire Medical Systems (NYSE: INSP).

### Related Stocks

- [INSP.US](https://longbridge.com/en/quote/INSP.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)
- [PODD.US](https://longbridge.com/en/quote/PODD.US.md)
- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)
- [KEY.US](https://longbridge.com/en/quote/KEY.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [KEY-K.US](https://longbridge.com/en/quote/KEY-K.US.md)
- [KEY-L.US](https://longbridge.com/en/quote/KEY-L.US.md)
- [KEY-J.US](https://longbridge.com/en/quote/KEY-J.US.md)
- [KEY-I.US](https://longbridge.com/en/quote/KEY-I.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Analyst Maintains Hold on Inspire as Reimbursement Uncertainty Persists; $53 Price Target Reaffirmed](https://longbridge.com/en/news/286682690.md)
- [NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation](https://longbridge.com/en/news/287094822.md)
- [09:00 ETMercy Names New Senior Vice President and Chief People Officer](https://longbridge.com/en/news/286775735.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)
- [Assessing Inspire Medical Systems (INSP) Valuation After Prolonged Share Price Weakness](https://longbridge.com/en/news/285275665.md)